Vizsgálati helyszín
Tokai University Hospital
Kanagawa, 259-1193, JapánMég nincs intézményhez kötve
- 13futó vizsgálat
- 4lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis13 vizsgálat
- 1/2. fázis1 vizsgálat
- 2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Lezárult2 vizsgálat
- Toboroz2 vizsgálat
- Még nem toboroz1 vizsgálat
- Leállították1 vizsgálat
- Visszavonták1 vizsgálat
- Fő szponzor
- Hoffmann-La Roche5 vizsgálat
- Gilead Sciences2 vizsgálat
- Incyte Biosciences Japan GK2 vizsgálat
- Biotronik SE & Co. KG1 vizsgálat
- Boehringer Ingelheim1 vizsgálat
- és még 6
Futó vizsgálatok
Toboroz
A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
NCT07319845· 2. fázis· Takeda· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06263478· 3. fázis· Incyte Biosciences Japan GK· Forrás
Toboroz
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995· 3. fázis· Eli Lilly and Company· Forrás
Contact: Koichiro Wasano (principal investigator)
Fut, nem toboroz
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT05840211· 3. fázis· Gilead Sciences· Forrás
Toboroz
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· 3. fázis· Genentech, Inc.· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382286· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007· 1/2. fázis· Incyte Biosciences Japan GK· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545· Biotronik SE & Co. KG· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek